The largest database of trusted experimental protocols

Ctla4 igg2a

Manufactured by BioXCell

CTLA4-IgG2a is a laboratory reagent that contains the fusion protein of the extracellular domain of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and the Fc region of murine immunoglobulin G2a (IgG2a). It is commonly used in research applications involving the study of T-cell activation and immune regulation.

Automatically generated - may contain errors

2 protocols using ctla4 igg2a

1

Tumor Immunotherapy Protocol in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
5×105 tumor cells were injected s.c. into mice, which formed tumors with a 1.5-cm diameter within 2–3 weeks of injection. Lipofermata was administrated s.c. at dose of 2 mg/kg twice per day. As a control, mice were treated with vehicle alone (DMSO + 30% v/v Kolliphor). Treatments with lipofermata started 8–10 days after tumors injections. CSF1R antibody (BioXcell, 300 μg/mouse) was administered every other day starting next day after tumor injection and continued until the mice were sacrificed. PD-1 antibody (clone RMP1–14, BioXcell, 200 μg/mouse) was administered twice a week started 10–12 days after tumor injection. CTLA4-IgG2a (BioXcell, 200 μg/mouse) was administered at day 7 and day 11.
+ Open protocol
+ Expand
2

Tumor Immunotherapy Protocol in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
5×105 tumor cells were injected s.c. into mice, which formed tumors with a 1.5-cm diameter within 2–3 weeks of injection. Lipofermata was administrated s.c. at dose of 2 mg/kg twice per day. As a control, mice were treated with vehicle alone (DMSO + 30% v/v Kolliphor). Treatments with lipofermata started 8–10 days after tumors injections. CSF1R antibody (BioXcell, 300 μg/mouse) was administered every other day starting next day after tumor injection and continued until the mice were sacrificed. PD-1 antibody (clone RMP1–14, BioXcell, 200 μg/mouse) was administered twice a week started 10–12 days after tumor injection. CTLA4-IgG2a (BioXcell, 200 μg/mouse) was administered at day 7 and day 11.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!